Other
Lenvatinib
0
Pipeline Programs↗
9
Active Trials↗
2
Companies Involved↗
Lenvatinib is an early-stage landscape with 0 programs across 2 companies. The most active players are Eisai, EMD Serono Research & Development Institute, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Unknown status6 · 33%
Not yet recruiting4 · 22%
Completed3 · 17%
Recruiting3 · 17%
Active, not recruiting2 · 11%
Clinical Trials
Trial Activity
18 trials
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06904196·78 enrolled
Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
Recruiting·—·Phase 1·NCT05803928·70 enrolled
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
Active, not recruiting·
EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05081180·17 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05081180·17 enrolledLenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
Not yet recruiting·—·Phase 1/2·NCT07096609·48 enrolled
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Unknown status·—·Phase 4·NCT04127396·72 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)